Over the last decade, the interest in low-dose ketamine for treatment of various indications like pain conditions, therapy-resistant depression and addiction has grown substantially. Discovered in the early 1960s, ketamine was developed for the induction of anesthesia and procedural sedation. Since then, and still today, the majority of ketamine is administered via the parenteral route, a route that requires sometimes-painful injection or venipuncture. In our LTS Academy session we will report on the latest research in the field of pain and ketamine. We will show that oral thin films (OTFs) are a convenient and attractive alternative dosage form for ketamine and other compounds. We will discuss promising results of a pharmacokinetic human study performed with transmucosal fast-dissolving oral thin films that contain S-ketamine, the positive effect seen in different pain models and the outcome of the used PK/PD modelling. Finally, we will also have a view on opportunities in an unsaturated growing market.

Learning objectives:

• In the LTS academy session you will learn about the role of ketamine in the treatment of pain.
• The sessions will show the components and science of OTFs and how they can be used to provide a genuine alternative to current drug delivery methods.
• You will learn about the outcome of LTS’ clinical study of a S-ketamine OTF in humans.
• The session will give you a first view on the market potential of a S-ketamine OTF in the treatment of pain.